Ther­at­e­ch­nolo­gies' HIV drug to face sup­ply is­sues in 2025 over third-par­ty fa­cil­i­ty shut­down 

An­oth­er phar­ma com­pa­ny is fac­ing sup­ply con­straints be­cause of third-par­ty con­tract man­u­fac­tur­ing is­sues.

On Tues­day, Ther­at­e­ch­nolo­gies warned there is a risk its lipody­s­tro­phy drug for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER